Novo Nordisk’s diabetes drug available in Europe in the first half of 2017
January 10, 2017European Commission has granted marketing authorisation for Novo Nordisk’s Fiasp for the treatment of diabetes in adults.
Fiasp is the brand name for fast-acting insulin aspart. It provides improved mealtime and overall glucose control with a similar safety profile versus NovoRapid, explained the company.
Fiasp will be available in vial, Penfill and FlexTouch pen.
Novo Nordisk expects to launch Fiasp in the first European countries in the first half of 2017.
“Fiasp is a new-generation mealtime insulin; it is an innovative faster formulation of insulin aspart that more closely mimics the physiological insulin response around meals. The incremental benefits with Fiasp are comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago”, said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.
